cliantha research

Ahead of Schedule Recruitment and Retention:

Key Determinants in a Successful Revefenacin Clinical Study in Chronic Obstructive Pulmonary Disease Indication (COPD)

Respiratory Case Study

Overview

An estimated 200 million people have COPD, of which about 3.2 million die each year, making it the third-leading cause of death worldwide. Revefenacin is a synthetic anticholinergic which inhibits the muscarinic actions of acetylcholine on autonomic nerve endings, which decreases bronchial smooth muscle contractions and can alleviate bronchospasm in patients with chronic obstructive pulmonary disease (COPD). Revefenacin has potent activity against muscarinic acetylcholine receptors found in bronchial smooth muscle (M3).

Developing effective treatments for respiratory disorders requires a CRO partner with the specialized expertise and relevant experience to address the complex challenges involved in such trials. Cliantha Research is full service global CRO with a unique approach to clinical development & is well suited to manage some of the industry's most complex and challenging respiratory clinical trials.

Molecule	**Nebulized Revefenacin Inhalation Solution**
Indication	**Moderate to Very Severe COPD**
Phase of Study	**Phase III**
Patients	**244 Randomized**
Sites	**20**

Challenges



Strategic Solution:

Cliantha Research adopted a “Site Swapping” recruitment approach to patient recruitment for this study, comprehensively covering the entire process from study awareness, through to randomization and patient retention. This aided in achieving the target enrollment objective ahead of the scheduled time.

Cliantha Advantages:

- An efficient study startup including regulatory support to drive streamlined approvals sooner than estimated
- Choosing high caliber PIs and sites to participate in the study
- Standardized training during key procedures of study led to high quality outcomes
- Successful recruitment of the right patient population and retaining patients in the study.
- Regular monitoring to keep PIs and their sites on track and to ensure high quality outcomes to form a discriminative and robust study for our sponsors.

What makes our sponsors choose us among competitors for respiratory clinical trials?

Conclusion

Patient recruitment completed within 75% of the stipulated time.



Contact Cliantha for more information about how we can make your patient-based trial successful.

For more information contact:
Ranjit Rajput, GM - Business Development
info@cliantha.com